课题基金 / 基金详情

Mucosal Immunization Against P. aeruginosa by Modified Adenovirus Vectors

Mucosal Immunization Against P. aeruginosa by Modified Adenovirus Vectors
改良腺病毒载体针对铜绿假单胞菌的粘膜免疫
批准号:
8579420
负责人:
Stefan Worgall
金额:
$39.81万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-05-16 至 2017-04-30

项目摘要

项目成果

Stefan Worgall的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Lung infections with Pseudomonas aeruginosa are a significant health problem for patients with bronchiectasis and cystic fibrosis. A vaccine against P. aeruginosa would be useful to prevent colonization and infection. Adenovirus vectors are efficient vaccine platforms for genetic vaccines and we have developed various Ad-based vaccines expressing the P. aeruginosa OprF protein. Our prior studies established that, the chimpanzee-based Ad vector (AdC7) expressing OprF and a peptide motif (RGD) that enhances infection of immune cells administered directly to the lung provides long term immunity and protection against P. aeruginosa. This project aims to evaluate AdC7RGD.OprF following administration to the lung in another rodent model and then develop a GLP-clinical AdC7RGD.OprF vector, including toxicology and efficacy evaluation in non-human primates. This would then lead to the clinical development of an AdC7-based vaccine for a clinical study.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Impact of SARS-CoV-2 infection on respiratory viral immune responses in children with and without asthma
Respiratory sphingolipid synthesis involved in airway hyperreactivity and viral-triggered asthma
Enhancing protective immunity against RSV by inhibitors of sphingolipid synthesis
Enhancing protective immunity against RSV by inhibitors of sphingolipid synthesis
海外基金